RNS Number: 3673 R Nuformix PLC 28 October 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 3668 R Nuformix PLC 28 October 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 3019 R Nuformix PLC 28 October 2019 28 October 2019. Following the receipt of Notice of Conversion of Loan Note, 8,716,512 ordinary shares of 0.1 p each in the Company have been issued to the Loan Note holder following exercise at the agreed price of 2.75 p per share.. Application has been made to admit the Loan Note Shares to trading on the London Stock...
RNS Number: 1806 R Nuformix PLC 25 October 2019 25th October 2019. Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs notes the recent share price movement and press reports. It confirms that the Company is in discussion with multiple potential licensees in...
RNS Number: 1620 R Nuformix PLC 25 October 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1618 R Nuformix PLC 25 October 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1609 N Nuformix PLC 20 September 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1591 N Nuformix PLC 20 September 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 8767 L Nuformix PLC 10 September 2019 10th September 2019. The Annual General Meeting of Nuformix plc was held on 10 th September 2019 at 1.00 pm, at the offices of Shakespeare Martineau LLP, 60 Gracechurch Street, London, EC3V 0 HR.. The Company's issued share capital is 469,466,512 ordinary shares of £0.001 each.
RNS Number: 7810 L Nuformix PLC 10 September 2019 10th September 2019. Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs announces the resignation of Kirk Siderman-Wolter from the Nuformix Board of Directors with immediate effect. The resolution to re-elect...
RNS Number: 6247 L Nuformix PLC 09 September 2019 9th September 2019. Ebers Tech Strategic Cannabinoid Collaboration Update. Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs is pleased to update shareholders on its collaboration with Ebers Tech Inc., a...
RNS Number: 4774 L Nuformix PLC 06 September 2019 6th September 2019. Appointment of Dr Muhunthan Thillai to Nuformix's Scientific. Dr Thillai began his training in London and Oxford where he gained Membership of the Royal College of Physicians.
RNS Number: 1623 L Nuformix PLC 04 September 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Cambridge, UK, 1 August 2019: Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, is pleased to announce that the following documents have been posted to its shareholders:. The Nuformix Annual Financial Report will be filed with the Registrar of Companies in due...
RNS Number: 9922 G Nuformix PLC 29 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Nuformix plc
NFX.L
Nuformix plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    469.72M

Featured Media

Company Profile

Nuformix is a pharmaceutical development company using cocrystal technology, unlocking the therapeutic potential of approved drugs with lead programmes in oncology supportive care and fibrosis.

Classification

Market Indices-

Locations

HQ
153 Cambridge Science Park
Milton Road
Cambridge
CB4 0GH
Watchlist